Shil Ie M, Kurman RJ.Ovarian tumorigenesis:a proposed model based on morphological and molecular genetic analysis[J].Am J Pathol,2004,164(5):1511-1518.
[2]
Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease[J].Trends Genet,2002,18:41？47.
[3]
Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development[J]. Nat Rev Cancer,2006,6:52？62.
[4]
Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of pax2 mediates tamoxifen-stimulated endometrial carcinogenesis[J].Nature, 2005,438(15):981-987.
[5]
Malpica A,Deavers MT,Lu K,et al.Grading ovarian serous carcinoma using a two-tier system[J].Am J Surg Pathol,2004,28(4):496-504.
O'Neill CJ,Deavers MT,Malpica A,et al. Animmunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas:significantly higher expression of p53,MIB1,BCL2,HER-2/neu,and C-KIT in high-grade neoplasms[J]. Am J Surg Pathol,2005,29(8):1034-1041.
[8]
Minamoto T,Mai M,Ronai Z.K-ras mutation early detection in molecular diagnosis and risk and assessment of colorectal pancreas and lung cancers[J].Cancer Detect Prev,2000,24(1):1-12.
Chan WY,Cheung KK,Schorge JO,et al.Bcl-2 and p53 protein expression,apoptosis, and p53 mutation in human epithelial ovarian cancers[J].Am J Pathol,2000,156(2):409-417.
[12]
O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms[J].Am J Surg Pathol,2005,29:1034？1041.
[13]
Celestine S Tung,Samuel C Mok,Yvonne TM Tsang. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas[J].Modern Pathology,2009, 22:1243-1250.
[14]
Drobnjak M, Latres E,Pollaek D,et al. PrognostieimPlications of P53 nuclear overexpression and high Proliferation index of Ki-67 in adult soft-tissue sarcomas[J]. J Natl Cancerhist, 1994,86(7):549-554.
[15]
Agoff SN, Lin P,Morihara J, et al. lp16(INK4A)exp ression correlates with degree of cervical neoPlasia: a comParison with Ki-67 expressionand detection of high-risk HPV types[J].Mod Pathol,2003,16,(7):665.
[16]
GoffB,Ries JA,Els L P,et al. Immunophenotype of ovarian cancer as predictor of clinical outcome:evaluation at primary surgery and second2look procedure[J].Gynecol Oncol,1998,70(3):378-385.
